PHARMANUTRA: insider trades · Italy · Consob

About PHARMANUTRA

PharmaNutra is an Italian listed healthcare company traded on Borsa Italiana (FTSE MIB) in Italy, focused on the research, development and commercialization of high-science food supplements and medical devices. The company was founded in 2003 in Pisa by brothers Andrea and Roberto Lacorte, and it has built its identity around innovation, proprietary know-how and a science-led approach to consumer and professional health products. Its headquarters are in Pisa, Via Campodavela 1, anchoring the group in a well-known Italian industrial and pharmaceutical cluster. ([pharmanutra.it](https://www.pharmanutra.it/en/company/)) PharmaNutra’s business model covers the full value chain, from research and formulation to regulatory registration and commercialization. Rather than competing primarily on price, the group emphasizes intellectual property, clinical evidence and proprietary ingredients. The company highlights 22 proprietary raw materials, 25 registered patents, 55 registered trademarks and 191 clinical and basic research studies, which underscores the depth of its scientific positioning and the defensibility of its product platform. ([pharmanutragroup.com](https://pharmanutragroup.com/en/)) In operational terms, PharmaNutra is best known for products and platforms linked to iron deficiency, minerals, vitamins, muscle and joint health, and broader nutraceutical applications. Its flagship brand family includes SiderAL®, which is built on the company’s Sucrosomial® Technology, a core differentiator in iron-based supplementation. The group also operates in adjacent health categories and expanded its scientific capabilities with the 2022 acquisition of Akern S.r.l., a company specializing in bioelectrical impedance analysis. That acquisition broadened the group’s offering and reinforced its medical-scientific profile. ([pharmanutragroup.com](https://pharmanutragroup.com/en/history/)) From a competitive perspective, PharmaNutra holds a strong niche position in Italy’s nutraceutical and specialty healthcare market. It combines an Italian heritage and “Made in Italy” brand appeal with a global commercialization footprint. According to the company, it operates in more than 80 countries worldwide, supported by foreign subsidiaries including PharmaNutra U.S.A. Corp. and PharmaNutra España. This international expansion is important because it reduces reliance on the domestic market and gives the company exposure to larger healthcare and consumer-health opportunities abroad. ([pharmanutragroup.com](https://pharmanutragroup.com/en/)) Recent news flow has been constructive. PharmaNutra published its 2024 annual report, continued advancing its international development strategy, and in 2026 announced FDA registration for its Pisa manufacturing facility. That FDA registration is strategically relevant because it strengthens the company’s regulatory standing and manufacturing setup for the U.S. market, enabling internal management of patented blends intended for American distribution. For equity investors, PharmaNutra therefore looks like a specialized healthcare platform with a defensible product base, international growth optionality and a relatively disciplined operating model on Borsa Italiana (FTSE MIB) in Italy. ([pharmanutragroup.com](https://pharmanutragroup.com/wp-content/uploads/2025/04/ANNUAL-FINANCIAL-REPORT-2024_ENG.pdf))